Clinical Outcome of Patients with Epithelioid Glioblastoma Harboring BRAFV600E Mutation; A Single Institution Experience
Epithelioid GBM is a very rare, but well-documented entity. Therefore, careful preoperative imaging and detailed evaluation of genetic studies including <i>BRAF</i> V600E mutation are necessary for accurate diagnosis and appropriate selection of treatment for epithelioid GBM. Dabrafenib plus trametinib showed clinically meaningful activity in patients with BRAF V600E mutation-positive recurrent high-grade glioma.
Authors
- Adhithyan Rajendran (ORCID: https://orcid.org/0009-0003-3506-4418)
- Rakesh Jalali (ORCID: https://orcid.org/0000-0002-0318-5536)
- Srinivas Chilukuri (ORCID: https://orcid.org/0000-0003-0491-7935)
- Anindita Das (ORCID: https://orcid.org/0000-0002-6828-2900)
- Preethi Subramanian
- Sushma Patil
- Roopesh Kumar
- Uday Krishna (ORCID: https://orcid.org/0000-0002-3498-4103)
- Sujith Kumar Mullapally
Institutions
- Apollo Proton Cancer Centre (IN)
Publication Details
- Journal
- South Asian Journal of Cancer
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1055/s-0044-1789605
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00